{"result": "(\"entity\"<|>TRIGLYCERIDES<|>ORGANIZATION<|>Triglycerides are a type of fat found in the blood, which are important for energy storage and metabolism, and are a key component in lipid emulsions used in nutrition.)\n##\n(\"entity\"<|>ACIDO LINOLEICO<|>PERSON<|>Linoleic acid is an essential fatty acid that is crucial for human health, particularly in preventing deficiencies in parenteral nutrition.)\n##\n(\"entity\"<|>NUTRICIÓN PARENTERAL<|>EVENT<|>Parenteral nutrition is a medical event where nutrients are provided intravenously, bypassing the usual process of eating and digestion, often used in patients who cannot eat by mouth.)\n##\n(\"entity\"<|>COLSTASIS<|>EVENT<|>Cholestasis is a medical condition characterized by reduced or stopped bile flow, which can occur in patients receiving prolonged parenteral nutrition.)\n##\n(\"entity\"<|>NEONATOS<|>PERSON<|>Neonates are newborn infants, particularly those who are premature or have low birth weight, often requiring specialized nutritional support.)\n##\n(\"entity\"<|>NIÑOS MAYORES<|>PERSON<|>Older children are those above the age of two years, who may have different nutritional needs compared to infants and neonates.)\n##\n(\"relationship\"<|>NUTRICIÓN PARENTERAL<|>COLSTASIS<|>Prolonged parenteral nutrition can lead to the development of cholestasis in patients, indicating a direct relationship between the two.<|>7)\n##\n(\"relationship\"<|>ACIDO LINOLEICO<|>NUTRICIÓN PARENTERAL<|>Linoleic acid is recommended for inclusion in parenteral nutrition to prevent essential fatty acid deficiency, showing a strong relationship.<|>9)\n##\n(\"relationship\"<|>NEONATOS<|>NUTRICIÓN PARENTERAL<|>Neonates often require parenteral nutrition due to their inability to feed orally, indicating a close relationship.<|>8)\n##\n(\"relationship\"<|>NIÑOS MAYORES<|>NUTRICIÓN PARENTERAL<|>Older children may also require parenteral nutrition in certain medical conditions, establishing a relationship between their needs and the nutrition method.<|>6)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: pidos deben formar parte de las soluciones de NP por su elevada densidad calórica, por ser fuente de ácidos grasos esenciales, por disminuir la osmolaridad de la solución y por evitar los efectos negativos de la sobrecarga de glucosa. Además, se ha demostrado que su adición a la NP mejora el balance de nitrógeno24. Se recomienda que constituyan del 25 al 40% de las calorías no proteicas. Para prevenir el déficit de ácidos grasos esenciales es suficiente la administración de 0,25 g/kg/día de ácido linoleico en RNPT y de 0,1 g/kg/día en RN a término y niños mayores. El aporte máximo recomendado es de 3-4 g/kg/día (0,13-0,17 g/kg/h) en lactantes y de 2-3 g/kg/día (0,08-0,13 g/kg/h) en niños mayores de 2 años12. Se recomienda incluirlos en la bolsa con el resto de los nutrientes (mezclas ternarias)25 e infundirlos a lo largo de 24 horas. En caso de ciclado de la parenteral, se infundirán durante el mismo tiempo que el resto de componentes de la NP. No existe evidencia de que aumentos progresivos en la cantidad de lípidos mejore su tolerancia, aunque aumentos de 0,5-1 g/kg/día, especialmente en RNPT, pueden ayudar a controlar la hipertrigliceridemia. Los niveles de triglicéridos en sangre se deben monitorizar siempre en pacientes que estén recibiendo lípidos por vía intravenosa, especialmente en aquellos casos de mayor riesgo de hiperlipidemia (RN de\n\nbajo peso, sepsis, hipercatabolismo, alta dosis de lípidos). Las cifras no deben superar la concentración de 150 mg/dl en pretérminos, 250 mg/dl en lactantes y 400 mg/dl en los niños mayores12.\n\nExisten diferentes tipos de soluciones lipídicas. La primera se comercializó en los años sesenta y estaba formada por triglicéridos de cadena larga (TCL) procedentes de aceite de soja (Intralipid®). Esta solución contenía pequeñas cantidades de ácidos grasos omega-3 y elevadas cantidades de omega-6, fundamentalmente ácido linoleico. A finales de los 80, aparecieron preparaciones mixtas que contenían un 50% de triglicéridos de cadena media (TCM) y 50% de TCL procedentes de aceite de soja (Lipofundina®). Los TCM ofrecían algunas ventajas teóricas frente a los TCL, como su hidrólisis preferencial por la lipoprotein lipasa, su metabolismo no-dependiente de carnitina o su rápida oxidación. A finales de los 90 apareció una nueva emulsión a base de aceite de oliva y de soja (Clinoleic®) (oliva:soja = 4:1), con menor cantidad de ácidos grasos poliinsaturados, una alta cantidad de ácido oleico y mayor cantidad también de vitamina E. Y más recientemente han aparecido nuevas soluciones a base de aceite de pescado (SMOFlipid®, Omegaven®, Lipoplus®). El aceite de pescado tiene algunas ventajas muy relevantes, como son su elevada concentración de alfa-tocoferol y la ausencia de fitoesteroles. Además, es una fuente rica en ácido docohexaenoico (DHA), muy importante para el neurodesarrollo y la función visual, así como en ácido eicosapentaenoico (EPA). El EPA desempeña un papel positivo en la regulación de la inflamación, tanto descendiendo la producción de citoquinas inflamatorias como aumentando de forma indirecta la secreción de IL-10, que es una citoquina antiinflamatoria. El aceite de pescado, además, reduce la lipogénesis de novo, estimula la betaoxidación y reduce la esteatosis hepática26. En la tabla 5 se recogen las soluciones lipídicas disponibles en nuestro medio con su composición.\n\nExisten multitud de estudios acerca del uso de los diferentes tipos de soluciones lipídicas en pediatría. Por ahora, no se ha podido demostrar que existan diferencias significativas con respecto a los parámetros de colestasis entre el uso de fórmulas a base de aceite de soja (Intralipid®) y las soluciones mixtas con aceite de pescado (SMOFlipid®; Lipoplus®) cuando se utilizan a corto plazo en neonatos o niños de mayor edad26. Se ha visto que en niños con nutrición parenteral prolongada, el uso de soluciones mixtas con aceite de pescado puede contribuir a proteger frente al desarrollo de colestasis26. Por último, la solución Omegaven®, a base únicamente de aceite de pescado, ha mostrado su eficacia en el tratamiento de resc\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>INTRALIPID<|>ORGANIZATION<|>Intralipid is a lipid emulsion solution that was first marketed in the 1960s, made from long-chain triglycerides derived from soybean oil, containing omega-3 and omega-6 fatty acids.)\n##\n(\"entity\"<|>LIPOFUNDINA<|>ORGANIZATION<|>Lipofundina is a mixed lipid preparation introduced in the late 1980s, consisting of 50% medium-chain triglycerides and 50% long-chain triglycerides from soybean oil.)\n##\n(\"entity\"<|>CLINOLEIC<|>ORGANIZATION<|>Clinoleic is a lipid emulsion introduced in the late 1990s, made from a blend of olive and soybean oil, designed to have a lower amount of polyunsaturated fatty acids and a higher amount of oleic acid.)\n##\n(\"entity\"<|>SMOFLIPID<|>ORGANIZATION<|>SMOFlipid is a newer lipid solution based on fish oil, known for its high concentration of alpha-tocopherol and absence of phytosterols, beneficial for pediatric nutrition.)\n##\n(\"entity\"<|>OMEGAVEN<|>ORGANIZATION<|>Omegaven is a fish oil-based lipid solution that has shown efficacy in treating certain conditions in pediatric patients.)\n##\n(\"entity\"<|>LIPOPLUS<|>ORGANIZATION<|>Lipoplus is another lipid emulsion that combines fish oil with other components, used in pediatric nutrition to prevent complications like cholestasis.)\n##\n(\"entity\"<|>EPA<|>PERSON<|>Eicosapentaenoic acid (EPA) is an omega-3 fatty acid that plays a role in regulating inflammation and is found in fish oil.)\n##\n(\"entity\"<|>DHA<|>PERSON<|>Docosahexaenoic acid (DHA) is an omega-3 fatty acid important for neurodevelopment and visual function, also found in fish oil.)\n##\n(\"relationship\"<|>INTRALIPID<|>LIPOFUNDINA<|>Lipofundina is a mixed lipid preparation that includes components similar to those found in Intralipid, indicating a relationship in their formulation and use in nutrition.<|>5)\n##\n(\"relationship\"<|>CLINOLEIC<|>SMOFLIPID<|>Both Clinoleic and SMOFlipid are lipid emulsions used in pediatric nutrition, with Clinoleic being based on olive oil and SMOFlipid on fish oil, showing a relationship in their application.<|>4)\n##\n(\"relationship\"<|>SMOFLIPID<|>OMEGAVEN<|>Both SMOFlipid and Omegaven are fish oil-based lipid solutions used in pediatric nutrition, indicating a relationship in their source and purpose.<|>5)\n##\n(\"relationship\"<|>LIPOPLUS<|>SMOFLIPID<|>Lipoplus and SMOFlipid are both lipid emulsions that include fish oil, suggesting a relationship in their formulation and use in preventing complications in pediatric patients.<|>5)\n##\n(\"relationship\"<|>DHA<|>SMOFLIPID<|>DHA is a key component of SMOFlipid, highlighting the relationship between the fatty acid and the lipid solution's benefits for neurodevelopment.<|>8)\n##\n(\"relationship\"<|>EPA<|>SMOFLIPID<|>EPA is another important fatty acid found in SMOFlipid, indicating its role in the solution's anti-inflammatory properties.<|>8)\n<|COMPLETE|>"}]}